Gene therapy aims to stop bladder scarring in painful bladder condition

NCT ID NCT07459790

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a gene therapy called Neovasculgen in 180 women with painful bladder syndrome and Hunner's lesions. The goal is to reduce scarring from previous treatments and prevent the bladder from shrinking. Participants receive either the drug or a placebo, and doctors check results using bladder cameras and symptom surveys over one year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER PAIN SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial cystitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Botkin Hospital

    RECRUITING

    Moscow, Russia

    Contact Phone: •••-•••-•••• Email: •••••@•••••